



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



MKC8866

Item No. 37332

CAS Registry No.: 1338934-59-0
Formal Name: 7-hydroxy-6-methoxy-4-methyl-3-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-2H-1-benzopyran-8-carboxaldehyde
Synonyms: Inositol-Requiring Enzyme 1 α Inhibitor 8866, IRE1-IN-8866
MF: C₁₈H₁₉NO₇
FW: 361.4
Purity: \geq 98%
UV/Vis.: λ_{max} : 259, 288, 324, 367 nm
Supplied as: A solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MKC8866 is supplied as a solid. A stock solution may be made by dissolving the MKC8866 in the solvent of choice, which should be purged with an inert gas. MKC8866 is soluble in the organic solvent dimethyl formamide (sonicated) at a concentration of approximately 1 mg/ml.

Description

MKC8866 is an inhibitor of inositol-requiring enzyme 1 α (IRE1 α) RNase activity (IC_{50} = 0.29 μ M).¹ It inhibits DTT-induced production of the IRE1 α target protein and transcription factor X-box binding protein 1 (XBP1) in MM.1S multiple myeloma cells (EC_{50} = 0.52 μ M) and XBP1 production induced by thapsigargin (Item No. 10522) in LNCaP cells (IC_{50} = 0.38 μ M). MKC8866 also decreases expression of the XBP1 target genes *SREBF1*, *DGAT2*, and *LIPE* and increases triglyceride levels in MDA-MB-231 cells.² *In vivo*, MKC8866 (300 mg/kg) reduces tumor volume in LNCaP, VCaP, 22Rv1, and C4-2B prostate cancer mouse xenograft models.¹

References

- Sheng, X., Nenseth, H.Z., Qu, S., *et al.* IRE1 α -XBP1s pathway promotes prostate cancer by activating c-MYC signaling. *Nat. Commun.* **10**(1), 323 (2019).
- Almanza, A., Mnich, K., Blomme, A., *et al.* Regulated IRE1 α -dependent decay (RIDD)-mediated reprogramming of lipid metabolism in cancer. *Nat. Commun.* **13**(1), 2493 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/08/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM